𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration

✍ Scribed by Alexander Gerhard; Justin Watts; Iris Trender-Gerhard; Federico Turkheimer; Richard B. Banati; Kailash Bhatia; David J. Brooks

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
176 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Corticobasal degeneration (CBD) is a neurodegenerative parkinsonian disorder of unknown cause that shows considerable clinical heterogeneity. In CBD, activated microglia have been shown to be associated closely with the extensive tau pathology found in the affected basal ganglia, brainstem nuclei, and cortical regions. We report on the use of ^11^C‐(1‐[2‐chlorophenyl]‐N‐methyl‐N‐[1‐methylpropyl]‐3‐isoquinoline carboxamide) (PK11195) positron emission tomography (PET), a marker of peripheral benzodiazepine binding sites (PBBS) that are expressed by activated microglia, to demonstrate in vivo the degree and distribution of glial response to the degenerative process in 4 patients with CBD. Compared with normal age‐matched controls, the CBD patient group showed significantly increased mean ^11^C‐PK11195 binding in the caudate nucleus, putamen, substantia nigra, pons, pre‐ and postcentral gyrus, and the frontal lobe. __11__C‐PK11195 PET reveals a pattern of increased microglial activation in CBD patients involving cortical regions and the basal ganglia that corresponds well with the known distribution of neuropathological changes, which may therefore help to characterize in vivo the underlying disease activity in CBD. © 2004 Movement Disorder Society

📜 SIMILAR VOLUMES

Imaging of activated microglia with PET
Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration
✍ Karsten Henkel; Jochen Karitzky; Michaela Schmid; Irina Mader; Gerhard Glatting; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

## Abstract Positron emission tomography (PET) using [^11^C]PK 11195, a ligand for peripheral benzodiazepine receptor binding sites, offers the opportunity to image activated microglia in vivo. This tool may therefore be used to display the occurrence of microglial activation in the course of neuro

In vivo imaging of microglial activation
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy
✍ Alexander Gerhard; Iris Trender-Gerhard; Federico Turkheimer; Niall P. Quinn; Ka 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

## Abstract Progressive supranuclear palsy (PSP) is a neurodegenerative disease presenting with voluntary gaze difficulties, early falls, and Parkinsonism. Neuronal loss, associated with intracellular neurofibrillary tangles and activated microglia, is found targeting the basal ganglia, brainstem n

Neuroinflammation in the pathophysiology
Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]-PK11195 PET
✍ Anna L. Bartels; Klaus L. Leenders 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract Increasing evidence suggests that neuroinflammation is an active process in Parkinson's disease (PD) that contributes to ongoing neurodegeneration. PD brains and experimental PD models show elevated cytokine levels and up‐regulation of inflammatory‐associated factors as cyclo‐oxygenase‐

In vivo imaging of brain lesions with [1
In vivo imaging of brain lesions with [11C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors
✍ Hervé Boutin; Fabien Chauveau; Cyrille Thominiaux; Bertrand Kuhnast; Marie-Claud 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB

## Abstract The peripheral benzodiazepine receptor (PBR) is expressed by microglial cells in many neuropathologies involving neuroinflammation. PK11195, the reference compound for PBR, is used for positron emission tomography (PET) imaging but has a limited capacity to quantify PBR expression. Here

Synthesis of [N-methyl-11C]-3-[(6-dimeth
Synthesis of [N-methyl-11C]-3-[(6-dimethylamino)pyridin-3-yl]-2,5-dimethyl-N, N-dipropylpyrazolo[1,5-a]pyrimidine-7-amine: A potential PET ligand for in vivo imaging of CRF1 receptors
✍ J.S. Dileep Kumar; Vattoly J. Majo; Jaya Prabhakaran; Norman R. Simpson; Ronald 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 138 KB

## Abstract A convenient synthesis of [N‐methyl‐^11^C]‐3‐[(6‐dimethylamino)pyridin‐3‐yl]‐2,5‐dimethyl‐__N__,__N__‐dipropylpyrazolo[1,5‐a]pyrimidine‐7‐amine (R121920), a highly selective CRF~1~ antagonist has been developed as a potential PET ligand. 3 ‐ [(6 ‐ methylamino)pyridin ‐ 3 ‐ yl]‐2,5‐dimet